Fidelity Investments’s Akcea Therapeutics Inc AKCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-5,716,836
| Closed | -$104M | – | 4474 |
|
|
2020
Q3 | $104M | Sell |
5,716,836
-4,894,782
| -46% | -$69.4M | 0.01% | 888 |
|
|
2020
Q2 | $145M | Sell |
10,611,618
-85,501
| -0.8% | -$1.32M | 0.02% | 725 |
|
|
2020
Q1 | $153M | Sell |
10,697,119
-99,021
| -0.9% | -$1.63M | 0.02% | 598 |
|
|
2019
Q4 | $183M | Sell |
10,796,140
-544,146
| -5% | -$10.1M | 0.02% | 681 |
|
|
2019
Q3 | $175M | Sell |
11,340,286
-899,203
| -7% | -$19.2M | 0.02% | 671 |
|
|
2019
Q2 | $287M | Sell |
12,239,489
-813,575
| -6% | -$20.1M | 0.03% | 515 |
|
|
2019
Q1 | $370M | Sell |
13,053,064
-328,442
| -2% | -$9.57M | 0.04% | 403 |
|
|
2018
Q4 | $403M | Buy |
13,381,506
+523,834
| +4% | +$14.7M | 0.06% | 345 |
|
|
2018
Q3 | $450M | Buy |
12,857,672
+402,289
| +3% | +$12.2M | 0.05% | 361 |
|
|
2018
Q2 | $295M | Buy |
12,455,383
+2,447,367
| +24% | +$58.4M | 0.03% | 505 |
|
|
2018
Q1 | $256M | Buy |
10,008,016
+26,772
| +0.3% | +$576K | 0.03% | 586 |
|
|
2017
Q4 | $173M | Buy |
9,981,244
+1,212,675
| +14% | +$23.8M | 0.02% | 745 |
|
|
2017
Q3 | $243M | Buy |
+8,768,569
| New | +$162M | 0.03% | 604 |
|
Fidelity Investments's AKCA Position: Q4 2020 in Review
Fidelity Investments sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 5,716,836 shares — an estimated $104M sold.
Fidelity Investments first reported a position in AKCA in Q3 2017 and held it in 13 quarters. The position peaked at $450M in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.
- Fidelity Investments reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
- Fidelity Investments sold 5,716,836 Akcea Therapeutics Inc shares in Q4 2020, an estimated $104M.
- Fidelity Investments first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 13 quarters.
- Fidelity Investments's Akcea Therapeutics Inc position peaked at $450M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.
Based on Fidelity Investments's 13F filing for Q4 2020, filed 8 Feb 2021.